Current Report Filing (8-k)
August 23 2022 - 3:11PM
Edgar (US Regulatory)
0001641631
false
0001641631
2022-08-23
2022-08-23
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date
of report (Date of earliest event reported): August 23, 2022
Beyond
Air, Inc.
(Exact
Name of Registrant as Specified in Charter)
Delaware |
|
001-38892 |
|
47-3812456 |
(State
or Other Jurisdiction
of
Incorporation) |
|
(Commission
File
Number) |
|
(I.R.S.
Employer
Identification
No.) |
900
Stewart Avenue, Suite 301
Garden
City, NY 11530
(Address
of Principal Executive Offices and Zip Code)
(516)
665-8200
Registrant’s
Telephone Number, Including Area Code
(Former
Name or Former Address, if Changed Since Last Report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):
|
☐ |
Written communication pursuant to
Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
|
|
☐ |
Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12) |
|
|
|
|
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
|
|
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
Common
Stock, par value $.0001 per share |
|
XAIR |
|
The
Nasdaq Stock Market LLC |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405)
or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
8.01. Other Events.
On
August 23, 2022, Beyond Air, Inc. (the “Company”) issued a press release (the “Press Release”) announcing that
Beyond Cancer, Ltd., an affiliate of the Company, has treated the first patient in a first-in-human Phase 1 clinical trial to assess
the safety and immune biomarkers of ultra-high concentration nitric oxide (UNO) therapy. A copy of the Press Release is attached hereto
and incorporated herein by reference in its entirety as Exhibit 99.1.
Item
9.01. Financial Statements and Exhibits.
(d)
Exhibits.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
BEYOND AIR, Inc. |
|
|
|
Date:
August 23, 2022 |
By: |
/s/
Steven A. Lisi |
|
Name: |
Steven
A. Lisi |
|
Title |
Chief
Executive Officer |
Beyond Air (NASDAQ:XAIR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Beyond Air (NASDAQ:XAIR)
Historical Stock Chart
From Apr 2023 to Apr 2024